Background The incidence of nosocomial infections from extensively drug-resistant
Pseudomonas aeruginosa (XDR-PA) has been increasing worldwide. We investigated the …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2.
Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …

Background Pleuritis is the most common pulmonary manifestation in systemic lupus
erythematosus (SLE). In Thailand, the incidence of tuberculosis (TB) is high; moreover, treatment …

We describe the first case of a psoas muscle abscess caused by Nocardia beijingensis and
subcutaneous phaeohyphomycosis caused by Phaeoacremonium parasiticum in a renal …

Objective: To investigate the clinical manifestations, diagnosis, etiology, management, and
outcomes of patients with systemic lupus erythematosus (SLE) and pericarditis Material and …

We reported a simple genome editing approach that can generate human immunodeficiency
virus-1 (HIV) coreceptor defective cells, which may be useful for latent viral eradication …

Thailand encountered its first coronavirus disease 2019 (COVID-19) outbreak in March
2020 and the Thailand Ministry of Public Health rapidly developed COVID-19 treatment …

We report the clinical outcomes following implementation of initial COVID-19 treatment
guidelines in Thailand. A composite poor outcome was defined as death, ICU admission, …

Background. Presently, data on effectiveness of triple combination of favipiravir, chloroquine-based
agents and protease inhibitors for treatment of covid-19 patients with pulmonary …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2.
Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …